News

Under the terms of the agreement, Boehringer Ingelheim will pay Micromet an upfront cash payment of approximately $6.6m. Micromet will be eligible to receive development and regulatory milestone

AEZS-108 is doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in

LX1031 is an oral, serotonin synthesis inhibitor that acts locally in the gastrointestinal tract targeting tryptophan hydroxylase (TPH), an enzyme necessary for the production of serotonin. LX1031 is

Intellipharmaceutics, Par, Novartis Pharmaceuticals, Novartis Pharma, Celgene, Elan and Elan Pharma, have also entered into license agreements in conjunction with the settlements of the litigation concerning the company’s

Pharmacokinetic data from the initial Phase I trial of BNC210 reported on March 3, 2010 indicated that a plateau of absorption of BNC210 was observed at doses between

With this solution, pharmaceutical, biopharmaceutical and medical device / equipment companies can partner with their contract manufacturers (CMOs) and packagers (CPOs) to create a common view of production

Oramed Pharmaceuticals said that the randomised, double-blind, placebo-controlled, multi-centered study conducted in South Africa evaluated responses of 29 type 2 diabetes patients to ORMD-0801. Insulin-loaded or placebo capsules

Ondansetron hydrochloride is the active ingredient in Zofran, GlaxoSmithKline’s drug to prevent chemotherapy and radiation related nausea and vomiting. As per the terms of the licensing agreement, RedHill

Exco InTouch said that the webinar, in collaboration with Novartis, discussed distinct advantages of ePRO (electronic reported outcomes) using cellphone technology, known in the industry as mPRO (mobile